Table 4 Cox proportional hazards model for attrition among PLWH on ART at Carmelo Hospital of Chókwè (2002–2019).

From: Predictors of attrition among adults in a rural HIV clinic in southern Mozambique: 18-year retrospective study

 

Total

Attrition

Attrition rate/100 py

Attrition

N

%

N

%

(overall = 9.46)

Hazard Ratio

Lower CI

Upper CI

p value

Gender

Male

6664

40.8

3471

50.3

7.02

–

–

–

 

Female

9657

59.2

3436

49.7

14.43

0.93

0.869

0.996

0.039

Age (years) , median (IQR)

Age band

55 + 

1231

7.5

543

7.9

10.49

–

–

–

 

15–24

1697

10.4

794

11.5

12.24

1.077

0.935

1.241

0.306

25–34

6190

37.9

2737

39.6

10.34

0.919

0.82

1.031

0.149

35–44

4713

28.9

1871

27.1

8.47

0.832

0.74

0.936

0.002

45–54

2490

15.3

962

13.9

7.53

0.922

0.812

1.046

0.207

Point of entry

Out-patient

13,890

85.1

4983

72.1

7.37

–

–

–

 

In-patient

2431

14.9

1924

27.9

35.60

3.18

2.894

3.495

 < 0.0001

CD4 + T-cell count (Cell/µL) , median (IQR)

CD4 + T-cell count (Cell/µL) Range

500 + 

1925

11.8

343

5.0

8.11

–

–

–

 

 < 50

2713

16.6

1817

26.3

22.28

1.91

1.626

2.242

 < 0.0001

50–99

2858

17.5

1270

18.4

8.20

1.182

1.006

1.388

0.042

100–199

2804

17.2

1272

18.4

9.27

1.171

0.996

1.378

0.057

200–349

4665

28.6

1729

25.0

6.69

1.024

0.874

1.201

0.767

350–499

1356

8.3

476

6.9

8.56

0.794

0.65

0.969

0.023

Previous ART exposition

ART non-naive

867

5.3

437

6.3

21.16

–

–

–

 

ART naive

15,454

94.7

6470

93.7

9.12

0.91

0.788

1.051

0.197

Previous Anti-TB Treatment

Unexposed to ATT initiation

10,490

67.0

2938

47.0

5.26

–

–

–

 

Complete ATT before ART initiation

511

3.3

206

3.3

7.62

1.476

1.215

1.794

 < 0.0001

Initiated ATT < 90 days after ART initiation

4667

29.8

3112

49.7

24.13

6.528

5.722

7.448

 < 0.0001

WHO clinical staging of HIV disease

Clinical stage IV

5495

33.7

3642

52.7

22.03

–

–

–

 

Clinical stage I

4501

27.6

1141

16.5

5.99

3.516

2.994

4.128

 < 0.0001

Clinical stage II

3588

22.0

1089

15.8

4.95

3.464

2.964

4.048

 < 0.0001

Clinical stage III

2737

16.8

1035

15.0

6.72

3.746

3.21

4.372

 < 0.0001

Kaposi Sarcoma

No Kaposi Sarcoma

16,022

98.2

6694

96.9

9.29

–

–

–

 

Kaposi Sarcoma

299

1.8

213

3.1

22.44

1.987

1.652

2.39

 < 0.0001

ART enrollment year

2019

436

2.7

53

0.8

20.85

–

–

–

 

2002

8

0.0

4

0.1

6.89

0.14

0.054

0.358

 < 0.0001

2003

77

0.5

24

0.3

2.74

0.31

0.182

0.526

 < 0.0001

2004

63

0.4

27

0.4

4.75

0.415

0.247

0.697

0.001

2005

234

1.4

105

1.5

5.56

0.318

0.216

0.467

 < 0.0001

2006

785

4.8

386

5.6

6.93

0.347

0.246

0.491

 < 0.0001

2007

1232

7.5

643

9.3

7.89

0.319

0.228

0.448

 < 0.0001

2008

1282

7.9

570

8.3

6.65

0.293

0.209

0.411

 < 0.0001

2009

1273

7.8

564

8.2

7.32

0.295

0.21

0.414

 < 0.0001

2010

1469

9.0

710

10.3

9.53

0.383

0.274

0.534

 < 0.0001

2011

1205

7.4

596

8.6

11.03

0.457

0.329

0.635

 < 0.0001

2012

1398

8.6

649

9.4

10.57

0.376

0.27

0.522

 < 0.0001

2013

1030

6.3

443

6.4

10.42

0.305

0.218

0.427

 < 0.0001

2014

1732

10.6

691

10.0

11.03

0.493

0.36

0.676

 < 0.0001

2015

1415

8.7

538

7.8

12.24

0.525

0.382

0.72

 < 0.0001

2016

1164

7.1

411

6.0

13.92

0.559

0.407

0.769

 < 0.0001

2017

844

5.2

305

4.4

18.92

0.761

0.553

1.046

0.092

2018

674

4.1

188

2.7

21.54

0.98

0.706

1.36

0.904

ART therapy initiation

TDF + 3TC + LPV/RTV

442

2.7

145

2.1

3.50

–

–

–

 

ABC + 3TC + EFV

56

0.3

30

0.4

31.57

3.978

2.589

6.111

 < 0.0001

ABC + 3TC + LPV/RTV

16

0.1

11

0.2

10.54

2.189

1.05

4.561

0.037

AZT + 3TC + ABC

203

1.2

109

1.6

12.40

2.984

2.152

4.139

 < 0.0001

AZT + 3TC + EFV

418

2.6

194

2.8

12.79

2.371

1.757

3.201

 < 0.0001

AZT + 3TC + LPV/RTV

52

0.3

19

0.3

4.07

0.695

0.336

1.438

0.327

AZT + 3TC + NVP

5511

33.8

1960

28.4

5.11

1.851

1.479

2.317

 < 0.0001

D4T + 3TC + ABC

531

3.3

406

5.9

34.91

6.497

5.055

8.35

 < 0.0001

D4T + 3TC + EFV

666

4.1

556

8.0

70.37

7.842

6.127

10.036

 < 0.0001

D4T + 3TC + LPV/RTV

3

0.0

2

0.0

6.78

0.778

0.107

5.634

0.803

D4T + 3TC + NVP

1588

9.7

1169

16.9

35.62

6.934

5.502

8.738

 < 0.0001

TDF + 3TC + DTG

68

0.4

1

0.0

3.92

0.477

0.113

2.004

0.312

TDF + 3TC + EFV

6767

41.5

2305

33.4

10.41

1.895

1.483

2.421

 < 0.0001

  1. 1p-values based on Cox regression proportional hazard risk.
  2. ART antiretroviral treatment, ABC abacavir, 3TC lamivudine, EFV efavirenz, LPV/RTV lopinavir/ritonavir, AZT zidovudine, D4T stavudine; NVP nevirapine, DGT dolutegravir.
Back to article page